substance p has been researched along with Angioneurotic Edema in 7 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (42.86) | 29.6817 |
2010's | 4 (57.14) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chowdhury, YS; Kostis, JB; Kostis, WJ; Shetty, M | 1 |
Chua, I; Kennedy, MA; Liau, Y; Maggo, S | 1 |
Aagaard, L; Andersen, MF; Buchwald, CV; Rasmussen, ER; Scott, SI | 1 |
Byrd, JS; Elsayed, R; Marshall, GD; Minor, DS | 1 |
Buclin, T; Grouzmann, E | 1 |
Adam, A; Brown, NJ; Byrd, JB; Gainer, JV; Nadeau, J; Sile, S; Touzin, K; Yu, C | 1 |
Akcali, C; Aynacioglu, AS; Benlier, N; Erbagci, Z; Ozkur, M | 1 |
3 review(s) available for substance p and Angioneurotic Edema
Article | Year |
---|---|
ACE Inhibitor-Induced Angioedema: a Review.
Topics: Adrenal Cortex Hormones; Angioedema; Angiotensin-Converting Enzyme Inhibitors; Bradykinin; Capillary Permeability; Combined Modality Therapy; Epinephrine; Female; Histamine Antagonists; Humans; Hypertension; Intubation, Intratracheal; Risk Factors; Substance P; Vasodilation | 2018 |
Pharmacogenetics of angiotensin-converting enzyme inhibitor-induced angioedema.
Topics: Angioedema; Angiotensin-Converting Enzyme Inhibitors; Bradykinin; Genome-Wide Association Study; Humans; Pharmacogenetics; Polymorphism, Genetic; Prevalence; Substance P | 2019 |
Dipeptidyl Peptidase-4 Inhibitor Induced Angioedema - An Overlooked Adverse Drug Reaction?
Topics: Angioedema; Angiotensin-Converting Enzyme Inhibitors; Animals; Bradykinin; Capillary Permeability; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Genetic Predisposition to Disease; Humans; Prognosis; Proteolysis; Risk Factors; Substance P; Vasodilation | 2018 |
4 other study(ies) available for substance p and Angioneurotic Edema
Article | Year |
---|---|
DPP-4 inhibitors and angioedema: a cause for concern?
Topics: Angioedema; Angiotensin-Converting Enzyme Inhibitors; Animals; Bradykinin; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypertension; Product Surveillance, Postmarketing; Substance P | 2011 |
Is dipeptidylpeptidase IV the missing link in angiotensin-converting enzyme inhibitor--induced angioedema?
Topics: Angioedema; Angiotensin-Converting Enzyme Inhibitors; Bradykinin; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Enzyme Inhibitors; Humans; Hypertension; Neprilysin; Peptidyl-Dipeptidase A; Substance P | 2008 |
Dipeptidyl peptidase IV in angiotensin-converting enzyme inhibitor associated angioedema.
Topics: Adult; Aged; Angioedema; Angiotensin-Converting Enzyme Inhibitors; Antigens; Bradykinin; Case-Control Studies; Dipeptidyl Peptidase 4; Female; Genetic Predisposition to Disease; Humans; Hypertension; Male; Middle Aged; Peptidyl-Dipeptidase A; Substance P | 2008 |
Association of insertion/deletion polymorphism of the angiotensin-converting enzyme gene with angio-oedema accompanying chronic urticaria but not chronic urticaria without angio-oedema or the autologous serum skin test response.
Topics: Adult; Alleles; Angioedema; Case-Control Studies; Chronic Disease; Disease Susceptibility; Female; Genotype; Humans; Male; Middle Aged; Peptidyl-Dipeptidase A; Polymorphism, Genetic; Substance P; Urticaria | 2008 |